source
- Carvykti shows 5-year survival in half of multiple myeloma patients in Phase 2 studyJohnson & Johnson and Legend Biotech reported that 10 of the 20 multiple myeloma patients treated with a single dose of Carvykti remained alive after a median follow‑up of 60.7 months, representing…
- RNAi biotech ADARx raises $446 million in IPO, secures $89 million from AbbVieADARx Pharmaceuticals priced its initial public offering at $17 per share, selling more than 26 million shares to raise about $446.3 million. The company also received an additional $89 million th…